UNSPSC 51384501: Alminoprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0255AHR9GJ, chemically known as propionic acid, 2-(4-(methallylamino)phenyl)- but generally known as alminoprofen, which bears US NIH Compound Identifier 2097. European Medicines Agency schedules Alminoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05347MIG.

UNSPSC 51384501 Alminoprofen is a Commodity code that shows minimal recent activity directly aligned with its narrow product scope. The code nominally designates a single active pharmaceutical ingredient (alminoprofen), yet the recent state and local solicitations tagged under it diverge substantially — they target naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals with various active ingredients, and prescription fulfillment programs rather than alminoprofen specifically. State and local purchasing offices appear to use this code as a catch-all for pharmaceutical procurement and related health-system acquisitions rather than as a precise marker for alminoprofen supply. When the code does appear in recent activity, it spans health departments, cooperative purchasing alliances, and county health agencies procuring pharmaceuticals and medical supplies to support community health and pharmacy benefit programs.

Recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026; and the Texas Health and Human Services Commission RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Activity clusters in Florida and across MMCAP cooperative member states (Minnesota and Oregon named), with exploratory procurement underway in Texas. The code shows limited decision-relevant recent volume — the mismatch between the code's nominal scope and actual solicitation content suggests limited pursuit opportunity unless your firm supplies broad pharmaceutical categories or participates in multi-state cooperative purchasing agreements.